nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutation
|
Gentzsch, Martina |
|
|
12 |
11 |
p. e67 |
artikel |
2 |
Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study
|
Li, Molly S C |
|
|
12 |
11 |
p. 840-842 |
artikel |
3 |
Antimicrobial resistance: a global health emergency
|
The Lancet Respiratory Medicine, |
|
|
12 |
11 |
p. 837 |
artikel |
4 |
Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis
|
Drent, Marjolein |
|
|
12 |
11 |
p. 848-851 |
artikel |
5 |
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial
|
Shiraishi, Yoshimasa |
|
|
12 |
11 |
p. 877-887 |
artikel |
6 |
Compassionate use trials and equitable access to variant-specific treatment for cystic fibrosis
|
Odem-Davis, Katherine |
|
|
12 |
11 |
p. 842-844 |
artikel |
7 |
Correction to Lancet Respir Med 2020; 8: 696–708
|
|
|
|
12 |
11 |
p. e70 |
artikel |
8 |
Correction to Lancet Respir Med 2024; 12: 888–900
|
|
|
|
12 |
11 |
p. e70 |
artikel |
9 |
Easing the stress of chronic cough
|
Dąbrowska, Marta |
|
|
12 |
11 |
p. 838-839 |
artikel |
10 |
Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial
|
Birring, Surinder S |
|
|
12 |
11 |
p. 855-864 |
artikel |
11 |
European Respiratory Society International Congress 2024
|
Venkatesan, Priya |
|
|
12 |
11 |
p. e71-e73 |
artikel |
12 |
Fatal dyspnoea at the Palace of Versailles
|
Drouin, Emmanuel |
|
|
12 |
11 |
p. 852-854 |
artikel |
13 |
Interactions between respiratory syncytial virus and Streptococcus pneumoniae in the pathogenesis of childhood respiratory infections: a systematic review
|
Besteman, Sjanna B |
|
|
12 |
11 |
p. 915-932 |
artikel |
14 |
New thinking and a new direction in bronchiectasis
|
Pavord, Ian D |
|
|
12 |
11 |
p. 844-845 |
artikel |
15 |
Phillip Morris sell Vectura after academic freeze-out
|
Burki, Talha |
|
|
12 |
11 |
p. e74 |
artikel |
16 |
Rethinking bronchiectasis as an inflammatory disease
|
Long, Merete B |
|
|
12 |
11 |
p. 901-914 |
artikel |
17 |
Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial
|
Sitbon, Olivier |
|
|
12 |
11 |
p. 865-876 |
artikel |
18 |
Serotonin pathway blockade in pulmonary arterial hypertension
|
Kurzyna, Marcin |
|
|
12 |
11 |
p. 839-840 |
artikel |
19 |
Spirometry in female individuals
|
Miller, Martin R |
|
|
12 |
11 |
p. e65 |
artikel |
20 |
Spirometry in female individuals – Authors' reply
|
Haouzi, Philippe |
|
|
12 |
11 |
p. e66 |
artikel |
21 |
Strengthening intensive care: addressing challenges and embracing opportunities
|
Azoulay, Elie |
|
|
12 |
11 |
p. 845-847 |
artikel |
22 |
The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
|
Burgel, Pierre-Régis |
|
|
12 |
11 |
p. 888-900 |
artikel |
23 |
Top ten research priorities for sepsis research: UK James Lind Alliance priority setting partnership
|
McPeake, Joanne |
|
|
12 |
11 |
p. e68-e69 |
artikel |